Version 1
: Received: 9 September 2024 / Approved: 10 September 2024 / Online: 11 September 2024 (07:43:11 CEST)
How to cite:
Sato, Y.; Motoishi, E.; Kakuba, R.; Nagatsuka, Y.; Abe, T.; Fujii, Y. Pharmacokinetic Evaluation of Dexmedetomidine in In Vivo Extracorporeal Membrane Oxygenation Rat Model. Preprints2024, 2024090799. https://doi.org/10.20944/preprints202409.0799.v1
Sato, Y.; Motoishi, E.; Kakuba, R.; Nagatsuka, Y.; Abe, T.; Fujii, Y. Pharmacokinetic Evaluation of Dexmedetomidine in In Vivo Extracorporeal Membrane Oxygenation Rat Model. Preprints 2024, 2024090799. https://doi.org/10.20944/preprints202409.0799.v1
Sato, Y.; Motoishi, E.; Kakuba, R.; Nagatsuka, Y.; Abe, T.; Fujii, Y. Pharmacokinetic Evaluation of Dexmedetomidine in In Vivo Extracorporeal Membrane Oxygenation Rat Model. Preprints2024, 2024090799. https://doi.org/10.20944/preprints202409.0799.v1
APA Style
Sato, Y., Motoishi, E., Kakuba, R., Nagatsuka, Y., Abe, T., & Fujii, Y. (2024). Pharmacokinetic Evaluation of Dexmedetomidine in In Vivo Extracorporeal Membrane Oxygenation Rat Model. Preprints. https://doi.org/10.20944/preprints202409.0799.v1
Chicago/Turabian Style
Sato, Y., Takuya Abe and Yutaka Fujii. 2024 "Pharmacokinetic Evaluation of Dexmedetomidine in In Vivo Extracorporeal Membrane Oxygenation Rat Model" Preprints. https://doi.org/10.20944/preprints202409.0799.v1
Abstract
Extracorporeal membrane oxygenation (ECMO) is increasingly used in intensive care units; however, ECMO can modify drug pharmacokinetics (PK), leading to underexposure and associated treatment failure. The aim of the present study was to determine the effect of ECMO on the PK of dexmedetomidine (DEX). In vivo rat models were developed, both of which involved a bolus injection of DEX and concentration monitoring. In the in vivo model experiment, rats which underwent ECMO were compared with a control group. PK analysis of in vivo data (noncompartmental analysis and nonlinear mixed-effects modelling) was carried out to determine the effect of ECMO. In vivo PK exploration showed that ECMO induced a decrease in DEX clearance. Because the effect of ECMO on the PK of DEX is not clinically significant, normal DEX dosing for critically ill patients should be effective for patients undergoing ECMO.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
